StockData

Can-Fite BioPharma vs Yarrow Bioscience

CANF and YARW side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CANF and YARW compare

Yarrow Bioscience grew revenue faster over the last twelve months (13.8% versus −39.9% for Can-Fite BioPharma).

Can-Fite BioPharma keeps more of each dollar of sales as profit, with a net margin of −2427% compared with −4646% at Yarrow Bioscience.

Yarrow Bioscience pays a dividend yielding 142%; Can-Fite BioPharma does not pay one.

Yarrow Bioscience scores higher on the StockData Score (11 against 1 for Can-Fite BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCANFYARW
Size and price
Market cap–$37.9M
Share price$1.53$14.21
Change, 1 year−79.3%−24.1%
Change, 5 years−99.4%−98.5%
Beta (5Y)1.472.07
Employees510
StockData Score
Total score111 (better)
Valuation score01 (better)
Growth score01 (better)
Performance score01 (better)
Health score15 (better)
Dividend score03 (better)
Valuation
P/S–66.6×
P/B–1.7×
FCF yield–−87.3%
Fair value–$7.04
Margin of safety–−102%
Growth
Revenue growth (TTM)−39.9%13.8% (better)
Revenue growth, 5Y average−11.9% (better)−51.4%
Profitability
Operating margin−2457% (better)−5219%
Net margin−2427% (better)−4646%
FCF margin−2210% (better)−5811%
Return on equity−217%−86.9% (better)
Financial health
Debt / equity–0.00
Interest coverage−35.0×–
Current ratio3.6015.26 (better)
Altman Z-score–−33.58
Piotroski F-score23 (better)
Dividends and buybacks
Dividend yield–142%
Shareholder yield–142%
Ownership
Held by institutions1.9%11.6%
Held by insiders0.00%82.1%
Short interest, % of float–29.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.